Analysis of antibody production in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

Analysis of antibody production in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. - Analysis of antibody production in patients with RA, AS and PsA.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42179

Enrollment

Registered

2015-03-31

Start date

2015-06-29

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatic diseases rheumatoid arthritis

Interventions

ankylosing spondylitis

antibodies

psoriatic arthritis

rheumatoid arthritis

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients with: - rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis - who are prescribed adalimumab, etanercept, golimumab, certolizumab pegol or abatacept by their rheumatologist - who gave written informed consent for the study

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
- Plasma: autoantibody and anti-drug antibody characteristics, drug level, other antibody responses related to treatment and disease, factors associated with inflammation (e.g. TNF). - Peripheral blood mononuclear cells (PBMCs): cell characteristics. - PBMC culture supernatant: Antibody production, cytokine production, production of factors associated with inflammation.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)